The addition of dexamethasone to dolasetron or haloperidol for treatment of established postoperative nausea and vomiting

Summary It is not known whether dexamethasone increases the effectiveness of anti‐emetics when given to treat postoperative nausea and vomiting (PONV). In a randomised study, 242 patients who were experiencing PONV received dolasetron and placebo, haloperidol and placebo, dolasetron and dexamethason...

Full description

Saved in:
Bibliographic Details
Published in:Anaesthesia 2007-08, Vol.62 (8), p.810-817
Main Authors: Rüsch, D., Arndt, C., Martin, H., Kranke, P.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Anesthesia
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antiemetics - therapeutic use
Biological and medical sciences
Dexamethasone - therapeutic use
Drug Therapy, Combination
Female
Haloperidol - therapeutic use
Humans
Indoles - therapeutic use
Male
Medical sciences
Middle Aged
Nausea
Pharmaceuticals
Postoperative Nausea and Vomiting - drug therapy
Postoperative Nausea and Vomiting - etiology
Postoperative period
Psychotropic drugs
Quinolizines - therapeutic use
Risk Factors
Serotonin Antagonists - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary It is not known whether dexamethasone increases the effectiveness of anti‐emetics when given to treat postoperative nausea and vomiting (PONV). In a randomised study, 242 patients who were experiencing PONV received dolasetron and placebo, haloperidol and placebo, dolasetron and dexamethasone, or haloperidol and dexamethasone. The results from 228 patients were suitable for analysis. PONV recurred significantly less frequently in patients treated with additional dexamethasone (33%) than in patients treated without additional dexamethasone (51%). The combination of dexamethasone with dolasetron or dexamethasone with haloperidol is superior to dolasetron or haloperidol alone for the treatment of PONV.
ISSN:0003-2409
1365-2044
DOI:10.1111/j.1365-2044.2007.05136.x